Around $1.3 billion of gross domestic product is allotted to diabetes care globally, according to research from the University of Göttingen and Harvard T.H. Chan School of Public Health. The substantial economic burden of the condition continues to grow, with the average annual cost of care in the U.S. rising 13% between 2012 and 2017. Current analysis of the high expenditure and prevalence suggests the need for policies and programs that prevent and treat diabetes. Improved treatment strategies could lead to notable economic benefits and the redirection of scarce health care resources towards other areas of need.
Insulin pump therapy, or continuous subcutaneous insulin infusion (CSII), has been used in the treatment of diabetes for decades. Devices have evolved with technological advancements; some insulin pumps now feature Bluetooth connectivity and complementary smartphone applications while the use of AI technology is slowly being integrated. Modern insulin pumps are both more patient and physician-friendly as they allow for precise insulin control in diabetic patients. As a result, the number of pump users has increased manifold now totaling an estimated 350,000 patients within the United States.